Patents by Inventor Catharina Emanuele Gerarda Havenith
Catharina Emanuele Gerarda Havenith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220177585Abstract: The invention relates to a method of characterizing an antibody, which method is suitable as a potency assay for batch release of a pharmaceutical composition comprising an antibody, specifically for use when applying for marketing authorization for said pharmaceutical composition. The assay provided is a method for determining the potency of a drug product comprising an FcR binding peptide, wherein at least one mechanism of action of the FcR binding peptide of the drug product is mediated through the binding of the FcR binding peptide of the drug product to a Fc receptor, wherein said method comprises determining the binding of the FcR binding peptide of the drug product to an Fc receptor.Type: ApplicationFiled: June 16, 2021Publication date: June 9, 2022Inventors: Catharina Emanuele GERARDA HAVENITH, Tom VINK, Patrick VAN BERKEL, Paul PARREN
-
Publication number: 20210107985Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: ApplicationFiled: May 26, 2020Publication date: April 15, 2021Inventors: Janine SCHUURMAN, Catharina Emanuele Gerarda HAVENITH, Paul PARREN, Jan G. J. VAN DE WINKEL, Denise Leah WILLIAMS, Jørgen PETERSEN, Ole BAADSGAARD
-
Patent number: 10703818Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: GrantFiled: January 31, 2017Date of Patent: July 7, 2020Assignee: GENMAB A/SInventors: Janine Schuurman, Catharina Emanuele Gerarda Havenith, Paul Parren, Jan G. J. Van De Winkel, Denise Leah Williams, Jørgen Petersen, Ole Baadsgaard
-
Publication number: 20170362319Abstract: The invention relates to a method of characterizing an antibody, which method is suitable as a potency assay for batch release of a pharmaceutical composition comprising an antibody, specifically for use when applying for marketing authorization for said pharmaceutical composition. The assay provided is a method for determining the potency of a drug product comprising an FcR binding peptide, wherein at least one mechanism of action of the FcR binding peptide of the drug product is mediated through the binding of the FcR binding peptide of the drug product to a Fc receptor, wherein said method comprises determining the binding of the FcR binding peptide of the drug product to an Fc receptor.Type: ApplicationFiled: January 24, 2017Publication date: December 21, 2017Inventors: Catharina Emanuele GERARDA HAVENITH, Tom VINK, Patrick VAN BERKEL, Paul PARREN
-
Publication number: 20170240640Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: ApplicationFiled: January 31, 2017Publication date: August 24, 2017Inventors: Janine SCHUURMAN, Catharina Emanuele Gerarda HAVENITH, Paul PARREN, Jan G. J. VAN DE WINKEL, Denise Leah WILLIAMS, Jørgen PETERSEN, Ole BAADSGAARD
-
Patent number: 9598493Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: GrantFiled: January 8, 2015Date of Patent: March 21, 2017Assignee: GENMAB A/SInventors: Janine Schuurman, Catharina Emanuele Gerarda Havenith, Paul Parren, Jan G. J. Van De Winkel, Denise Leah Williams, Jørgen Petersen, Ole Baadsgaard
-
Patent number: 9580506Abstract: The invention relates to a method of characterizing an antibody, which method is suitable as a potency assay for batch release of a pharmaceutical composition comprising an antibody, specifically for use when applying for marketing authorization for said pharmaceutical composition. The assay provided is a method for determining the potency of a drug product comprising an FcR binding peptide, wherein at least one mechanism of action of the FcR binding peptide of the drug product is mediated through the binding of the FcR binding peptide of the drug product to a Fc receptor, wherein said method comprises determining the binding of the FcR binding peptide of the drug product to an Fc receptor.Type: GrantFiled: July 21, 2006Date of Patent: February 28, 2017Assignee: GENMAB A/SInventors: Catharina Emanuele Gerarda Havenith, Tom Vink, Patrick Van Berkel, Paul Parren
-
Publication number: 20150259424Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: ApplicationFiled: January 8, 2015Publication date: September 17, 2015Inventors: Janine SCHUURMAN, Catharina Emanuele Gerarda HAVENITH, Paul PARREN, Jan G.J. VAN DE WINKEL, Denise Leah WILLIAMS, Jørgen PETERSEN, Ole BAADSGAARD
-
Patent number: 8961968Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: GrantFiled: May 7, 2012Date of Patent: February 24, 2015Assignee: Genmab A/SInventors: Janine Schuurman, Catharina Emanuele Gerarda Havenith, Paul Parren, Jan G. J. Van De Winkel, Denise Leah Williams, Jørgen Petersen, Ole Baadsgaard
-
Publication number: 20120244069Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: ApplicationFiled: May 7, 2012Publication date: September 27, 2012Applicant: GENMAB A/SInventors: Janine SCHUURMAN, Catharina Emanuele Gerarda HAVENITH, Paul PARREN, Jan G. J. VAN DE WINKEL, Denise Leah WILLIAMS, Jørgen PETERSEN, Ole BAADSGAARD
-
Patent number: 8182812Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: GrantFiled: September 16, 2008Date of Patent: May 22, 2012Assignee: Genmab A/SInventors: Janine Schuurman, Catharina Emanuele Gerarda Havenith, Paul Parren, Jan G. J. Van De Winkel, Denise Leah Williams, Jorgen Petersen, Ole Baadsgaard
-
Publication number: 20100015644Abstract: The invention relates to a method of characterizing an antibody, which method is suitable as a potency assay for batch release of a pharmaceutical composition comprising an antibody, specifically for use when applying for marketing authorization for said pharmaceutical composition. The assay provided is a method for determining the potency of a drug product comprising an FcR binding peptide, wherein at least one mechanism of action of the FcR binding peptide of the drug product is mediated through the binding of the FcR binding peptide of the drug product to a Fc receptor, wherein said method comprises determining the binding of the FcR binding peptide of the drug product to an Fc receptor.Type: ApplicationFiled: July 21, 2006Publication date: January 21, 2010Inventors: Catharina Emanuele Gerarda Havenith, Tom Vink, Van Berkel Patrick, Paul Parren
-
Publication number: 20090081219Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: ApplicationFiled: September 16, 2008Publication date: March 26, 2009Applicant: GENMAB A/SInventors: Janine Schuurman, Catharina Emanuele Gerarda Havenith, Paul Parren, Jan G.J. Van De Winkel, Denise Leah Williams, Jorgen Petersen, Ole Baadsgaard
-
Patent number: 7438907Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: GrantFiled: November 14, 2003Date of Patent: October 21, 2008Assignee: Genmab A/SInventors: Janine Schuurman, Catharina Emanuele Gerarda Havenith, Paul Parren, Jan G. J. Van De Winkel, Denise Leah Williams, Jørgen Petersen, Ole Baadsgaard
-
Publication number: 20040170626Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: ApplicationFiled: November 14, 2003Publication date: September 2, 2004Applicant: GENMAB, INC.Inventors: Janine Schuurman, Catharina Emanuele Gerarda Havenith, Paul Parren, Jan G.J. Van De Winkel, Denise Leah Williams, Jorgen Petersen, Ole Baadsgaard D.M. Sc.